# mRNA * **Definition:** A type of messenger RNA that instructs cells to produce proteins, triggering an immune response or combating diseases, commonly used in vaccines and therapeutics. * **Taxonomy:** Healthcare Topics / mRNA ## News * Selected news on the topic of **mRNA**, for healthcare technology leaders * 7.7K news items are in the system for this topic * Posts have been filtered for tech and healthcare-related keywords | Date | Title | Source | | --- | --- | --- | | 5/17/2025 | [**mRNA Vaccine and Therapeutics Raw Material Market Acceleration 2025 - LinkedIn**](https://www.linkedin.com/pulse/mrna-vaccine-therapeutics-raw-material-market-acceleration-208ne) | [[Linkedin]] | | 5/2/2025 | [**Why It Would Be Utter Madness to Stop Funding mRNA Vaccine Technology - Medium**](https://medium.com/@seobgs012/why-it-would-be-utter-madness-to-stop-funding-mrna-vaccine-technology-4b2702305619) | [[Medium]] | | 4/15/2025 | [**MRNA Synthesis & Manufacturing Market Research Report 2025 and Global Forecasts to 2029**](https://finance.yahoo.com/news/mrna-synthesis-manufacturing-market-research-083500049.html) | [[Yahoo Finance]] | | 4/15/2025 | [**Re-adenylation by TENT5A enhances efficacy of SARS-CoV-2 mRNA vaccines**](https://www.nature.com/articles/s41586-025-08842-1) | [[Nature]] | | 4/10/2025 | [**Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA ...**](https://finance.yahoo.com/news/arcturus-therapeutics-receives-u-fda-120000445.html) | [[Yahoo Finance]] | | 4/3/2025 | [**Cellular regulator of mRNA vaccine revealed, offering new therapeutic options**](https://phys.org/news/2025-04-cellular-mrna-vaccine-revealed-therapeutic.html) | [[Phys Org]] | | 3/23/2025 | [**AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI ...**](https://www.prnewswire.com/apac/news-releases/aim-vaccines-mrna-shingles-vaccine-approved-by-the-us-fda-to-begin-clinical-trials-ai-enabled-mrna-major-vaccine-product-development-accelerates-302408598.html) | [[PR Newswire]] | | 3/23/2025 | [**AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI ...**](https://finance.yahoo.com/news/aim-vaccines-mrna-shingles-vaccine-000000375.html) | [[Yahoo Finance]] | | 3/18/2025 | [**mRNA Vaccines Market Trends and Competition Analysis 2025-2030 - Yahoo Finance**](https://finance.yahoo.com/news/mrna-vaccines-market-trends-competition-092000625.html) | [[Yahoo Finance]] | | 3/11/2025 | [**mRNA Cancer Therapeutics Patent Landscape Report and Forecast 2024-2032 ... - Yahoo Finance**](https://finance.yahoo.com/news/mrna-cancer-therapeutics-patent-landscape-152200084.html) | [[Yahoo Finance]] | | 2/25/2025 | [**SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate**](https://www.prnewswire.com/news-releases/sk-bioscience-initiates-global-clinical-trials-of-mrna-japanese-encephalitis-vaccine-candidate-302384523.html) | [[PR Newswire]] | | 2/11/2025 | [**Piezo Therapeutics Unveils Positive Preclinical Data Demonstrating LNP-Free mRNA Vaccine Delivery**](https://www.prweb.com/releases/piezo-therapeutics-unveils-positive-preclinical-data-demonstrating-lnp-free-mrna-vaccine-delivery-302372062.html) | [[PRWeb]] | | 1/22/2025 | [**Revolutionizing mRNA Analytics: Rapid Quantification for Multivalent Vaccine Development, Upcoming Webinar Hosted by Xtalks**](https://www.prweb.com/releases/revolutionizing-mrna-analytics-rapid-quantification-for-multivalent-vaccine-development-upcoming-webinar-hosted-by-xtalks-302357462.html) | [[PRWeb]] | | 1/10/2025 | [**Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial**](https://finance.yahoo.com/news/arcturus-therapeutics-announces-initiation-phase-130000469.html) | [[Yahoo Finance]] | | 1/10/2025 | [**Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial**](http://www.businesswire.com/news/home/20250110432449/en/Arcturus-Therapeutics-Announces-Initiation-of-Phase-1-H5N1-Flu-Vaccine-Trial/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 12/11/2024 | [**mRNA Vaccines and Therapeutics Industry Forecast to Generate Over $72 Billion in ...**](https://finance.yahoo.com/news/mrna-vaccines-therapeutics-industry-forecast-091800180.html) | [[Yahoo Finance]] | | 12/9/2024 | [**Novel mixture of mRNA in nanoparticles show therapeutic potential against tumor progression**](https://phys.org/news/2024-12-mixture-mrna-nanoparticles-therapeutic-potential.html) | [[Phys Org]] | | 12/8/2024 | [**mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in ...**](https://finance.yahoo.com/news/mrna-therapeutics-market-size-hit-130000272.html) | [[Yahoo Finance]] | | 11/21/2024 | [**Lipid nanoparticle-mRNA delivery system could transform neurological treatment**](https://medicalxpress.com/news/2024-11-lipid-nanoparticle-mrna-delivery-neurological.html) | [[MedicalXpress]] | | 10/30/2024 | [**Opportunities for innovation and flexibility in mRNA and LNP manufacturing**](https://www.fiercepharma.com/sponsored/opportunities-innovation-and-flexibility-mrna-and-lnp-manufacturing) | [[FiercePharma]] | | 10/29/2024 | [**mRNA Synthesis uring Market to Hit USD 2958.3 million by 2029 with 5.8AGR - MarketsandMarkets™**](https://www.globenewswire.com/news-release/2024/10/29/2970798/0/en/mRNA-Synthesis-Manufacturing-Market-to-Hit-USD-2958-3-million-by-2029-with-5-8-CAGR-MarketsandMarkets.html) | [[Globe Newswire]] | | 10/29/2024 | [**mRNA Synthesis & Manufacturing Market to Hit USD 2958.3 million by 2029 with 5.8AGR**](https://finance.yahoo.com/news/mrna-synthesis-manufacturing-market-hit-123000845.html) | [[Yahoo Finance]] | | 10/24/2024 | [**Steps towards licensure of self-amplifying RNA vaccines - The Lancet Infectious Diseases**](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00593-0/abstract) | [[The Lancet]] | | 10/24/2024 | [**Steps towards licensure of self-amplifying RNA vaccines - The Lancet Infectious Diseases**](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00593-0/fulltext?rss=yes) | [[The Lancet]] | | 10/16/2024 | [**mRNA Synthesis & Manufacturing Market to Hit USD 738.3 Million by 2029 with 3.4AGR**](https://www.prnewswire.com/news-releases/mrna-synthesis--manufacturing-market-to-hit-usd-738-3-million-by-2029-with-3-4-cagr--marketsandmarkets-302277596.html) | [[PR Newswire]] | ## Topic Overview (Some LLM-derived content — please confirm with above primary sources) ### Key Players - **Moderna**: A biotechnology company known for its mRNA COVID-19 vaccine, actively involved in the development of mRNA therapeutics. - **ExPLoRNA Therapeutics**: Focuses on innovative mRNA capping technologies to enhance protein production and therapeutic effectiveness. - **Primrose Bio**: A biotechnology company specializing in high-performance RNA polymerases for mRNA synthesis. - **Gritstone Bio**: A leader in self-amplifying mRNA (samRNA) development, facing financial struggles amid increasing confidence in traditional mRNA vaccines. - **Nature's Toolbox (NTx)**: A company that has developed a rapid mRNA production system, NTxscribe, for scalable and affordable mRNA manufacturing. - **CureVac**: A biopharmaceutical company specializing in mRNA technology for therapeutic applications. - **AIM Vaccine Co., Ltd.**: A Chinese company recognized for its mRNA shingles and RSV vaccines, showcasing rapid progress in mRNA technology. - **Arcturus Therapeutics**: A company specializing in mRNA medicines, known for its self-amplifying mRNA vaccine candidate ARCT-2304 for H5N1 influenza. - **CancerVax, Inc.**: A company developing Smart mRNA technology for targeted cancer therapies. - **Strand Therapeutics**: A company developing programmable mRNA therapies for targeted cancer treatment. - **CSL**: A global biotechnology company involved in the development of self-amplifying mRNA vaccines. - **Exsilio Therapeutics**: A startup focused on developing genomic medicines using mRNA technology, led by Tal Zaks, former Moderna executive. ### Partnerships and Collaborations - **Thermo Fisher Scientific**: Provides comprehensive solutions for mRNA-based products, addressing the entire operational value chain. - **Primrose Bio and ExPLoRNA Therapeutics**: Strategic partnership to develop and market mRNA medicines, addressing manufacturing challenges. - **WHO and Medicines Patent Pool**: Partnering to enhance mRNA vaccine production capabilities in low- and middle-income countries. - **Merck and Afrigen Biologics**: A partnership to enhance mRNA vaccine technology and manufacturing capabilities in low- and middle-income countries. - **VIB, VUB, Ghent University, and eTheRNA Immunotherapies**: Collaborating on a lipid-based nanoparticle platform to enhance mRNA therapeutic efficacy. - **ImmunoPrecise Antibodies and RIBOPRO**: Strategic collaboration to improve therapeutic antibody discovery through mRNA and lipid nanoparticle integration. - **Moderna and Merck**: Collaborating on mRNA cancer vaccines, showing promising results in treating high-risk melanoma patients. - **Emerson and AspenTech**: Collaboration providing solutions for mRNA therapy production, enhancing scalability and compliance. - **Nagoya University and UC Davis**: Developing new synthesis technology for high-purity mRNA and exploring its applications in gene editing and vaccine development. - **University of Pennsylvania**: Researching ionizable lipids for improved mRNA delivery systems, enhancing vaccine effectiveness. - **Quantoom Biosciences and DIANT Pharma**: A strategic collaboration aimed at optimizing the supply chain for mRNA through improved lipid nanoparticle processing. - **Meiji Seika Pharma and ARCALIS**: Joint venture to establish domestic production of mRNA vaccines in Japan. - **CancerVax and Flashpoint Therapeutics**: Collaboration to validate Smart mRNA technology in various cancer cell lines. - **CureVac and ARCT-2301**: CureVac is collaborating on the development of self-amplifying mRNA vaccines. - **Sinergium Biotech and WHO**: Working together to develop H5N1 mRNA vaccine candidates. - **CEPI and SK bioscience**: Collaborating to develop mRNA vaccines for Japanese encephalitis and Lassa fever, with significant funding to support early trials. - **Arcturus Therapeutics and CSL Seqirus**: Collaborating on innovative mRNA vaccines, including the self-amplifying mRNA COVID-19 vaccine. - **Moderna and Cenra Healthcare**: Joint agreement to co-promote Moderna's mRNA respiratory vaccine portfolio in Taiwan. - **Biden Administration and Moderna/Pfizer**: Investment in mRNA vaccine development targeting emerging biothreats, particularly bird flu. - **CSL and Arcturus Therapeutics**: Collaboration to develop and distribute the KOSTAIVE self-amplifying mRNA COVID-19 vaccine in Japan. ### Innovations, Trends, and Initiatives - **mRNA in Cancer Treatment**: Synthetic mRNA developed to enhance immune response against metastatic cancer cells, showing promise in preclinical studies. - **mRNA Sequencing**: Emerging as a key technology for analyzing gene expression, with significant growth anticipated due to precision medicine demands. - **mRNA for Infectious Diseases**: The success of COVID-19 vaccines has spurred interest in mRNA applications for other infectious diseases and personalized medicine. - **mRNA Therapeutics Market Growth**: The market is expanding due to the success of COVID-19 vaccines, with increasing investments in mRNA technologies for various diseases. - **mRNA stability research**: Studies at the Max Planck Institute exploring methods to inhibit mRNA degradation, paving the way for innovative mRNA therapies. - **mRNA Cancer Therapeutics**: Research is focusing on mRNA's potential in treating various cancers, with over 235 drug candidates in development. - **mRNA Delivery Technologies**: Advancements in lipid and polymeric nanoparticles aim to improve mRNA stability and cellular uptake for safer therapies. - **mRNA Vaccine Development**: Significant advancements in mRNA technology have led to rapid vaccine development, particularly during the COVID-19 pandemic. - **mRNA Cancer Vaccines**: Research is ongoing into mRNA vaccines for cancer treatment, with significant growth expected in the market, particularly in the U.S. and China. - **Self-amplifying mRNA (samRNA) technology**: Demonstrating superior immunogenicity and potential for lower doses in vaccine development, with ongoing studies to clarify clinical relevance. - **NTx Services**: Launch of a new service for producing high-integrity mRNA, enhancing scalability and flexibility in mRNA production. - **New synthesis technology for mRNA**: Developed by Nagoya University, this technology aims to speed up vaccine production and improve purity, addressing challenges in mRNA manufacturing. - **Lipid nanoparticles**: Critical for mRNA delivery, with ongoing research to improve their effectiveness and safety. - **mRNA-based cancer vaccines**: Research focusing on eliciting robust immune responses against solid tumors, with funding from the American Cancer Society. - **Self-Amplifying mRNA Technology**: Emerging as a promising approach for longer-lasting immunity and enhanced immune responses. - **AI-assisted mRNA Design**: Sanyou Bio's platform utilizes AI to optimize mRNA stability and translation efficiency, streamlining the development process. - **Thermostable mRNA formulations**: PopVax's initiative to create stable mRNA vaccines for easier distribution in emergencies. ### Challenges and Concerns - **Cellular Uptake Issues**: Therapeutic mRNAs face challenges with poor cellular uptake when delivered as naked mRNA, necessitating advanced delivery systems. - **Stability of mRNA**: mRNA is inherently unstable, necessitating effective delivery systems to ensure therapeutic efficacy. - **Cost of Production**: The complex and costly nature of mRNA production leads developers to explore outsourcing as a solution. - **Regulatory Hurdles**: As mRNA technologies advance, navigating regulatory pathways for new therapies remains a significant challenge. - **Regulatory resistance to samRNA**: Challenges in gaining acceptance and investment in self-amplifying mRNA technology due to a knowledge gap compared to established mRNA therapeutics. - **Delivery System Limitations**: Challenges in ensuring stability and effective delivery of varying lengths of nucleic acids in mRNA therapies. - **Intellectual property issues**: Access to materials for mRNA synthesis can be complicated by existing patents. - **High production costs**: Continues to hinder the growth of the mRNA synthesis and manufacturing market despite rising demand for personalized medicine. - **Market Decline**: The global mRNA market is projected to decline from $149.9 billion in 2023 to $120.2 billion by 2030, indicating potential market saturation. - **Public Perception of mRNA Vaccines**: Concerns regarding vaccine hesitancy and misinformation, particularly with incoming health officials' stances on mRNA technology. - **Production costs and scalability**: High production costs and stability issues remain significant challenges in the mRNA market. - **Manufacturing Challenges**: Scaling production of mRNA therapies is complex due to regulatory requirements and the need for advanced manufacturing processes. - **Regulatory hurdles**: Navigating regulatory landscapes for new mRNA therapies can be complex and time-consuming. - **Data Availability**: Limited comprehensive data on mRNA cancer vaccines and mixed results from clinical trials. - **Skepticism and Safety Concerns**: Public skepticism, particularly among certain political groups, poses a risk to the acceptance and future development of mRNA technologies. - **Regulatory and Political Opposition**: Legislation to ban or restrict mRNA vaccines has been introduced in several states, raising concerns about public health and future medical advancements. - **Regulatory Challenges**: The UK MHRA is developing new regulatory guidance for personalized mRNA cancer immunotherapies, highlighting the need for tailored regulations.